Brian A Fox (Brian Fox)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Cancer research communications

Molecular cancer therapeutics

Blood advances

Scientific reports

Celgene Corp

University of Washington (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Celgene Corp

United States

Sr Principal Scientist

Needle Genomics LLC

United States

Founder

Immunexpress

United States

Principal Scientist

Education History

University of Washington

United States

PHD :: Biochemistry

Publications

Henry Chan, Christina V Trout, David Mikolon, Preston Adams, Roberto Guzman, Konstantinos Mavrommatis, Mahan Abbasian, Haralambos Hadjivassiliou, Lawrence Dearth, Brian A Fox, Pallavur Sivakumar, Ho Cho, Kandasamy Hariharan
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies. Cancer research communications 4 (2) (2024)
Henry Chan, Christina V Trout, David Mikolon, Preston Adams, Roberto Guzman, Konstantinos Mavrommatis, Mahan Abbasian, Haralambos Hadjivassiliou, Lawrence Dearth, Brian A Fox, Pallavur Sivakumar, Ho Cho, Kandasamy Hariharan
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies. Cancer research communications 4 (2) (2024)
Henry Chan, Christina V Trout, David Mikolon, Preston Adams, Roberto Guzman, Konstantinos Mavrommatis, Mahan Abbasian, Haralambos Hadjivassiliou, Lawrence Dearth, Brian A Fox, Pallavur Sivakumar, Ho Cho, Kandasamy Hariharan
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies. Cancer research communications 4 (2) (2024)
Henry Chan, Christina V Trout, David Mikolon, Preston Adams, Roberto Guzman, Konstantinos Mavrommatis, Mahan Abbasian, Haralambos Hadjivassiliou, Lawrence Dearth, Brian A Fox, Pallavur Sivakumar, Ho Cho, Kandasamy Hariharan
Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα that Enhances Macrophage-Mediated Tumor Phagocytosis when Combined with Opsonizing Antibodies. Cancer research communications (2024)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
N Eric Olson, Seamus P Ragan, David J Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S Abramson, Candice McCoy, Kathryn J Newhall, Brian A Fox
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular cancer therapeutics 22 (3) (2023)
Amer M Zeidan, Isaac Boss, C L Beach, Wilbert B Copeland, Ethan Thompson, Brian A Fox, Vanessa E Hasle, Andrzej Hellmann, David C Taussig, Mar Tormo, Maria Teresa Teresa Voso, James Cavenagh, Tim O'Connor, Alessandro Previtali, Shelonitda Rose, Lewis R Silverman
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood advances 6 (7) (2022)
Amer M Zeidan, Isaac Boss, C L Beach, Wilbert B Copeland, Ethan Thompson, Brian A Fox, Vanessa E Hasle, Ken Ogasawara, James Cavenagh, Lewis R Silverman, Maria Teresa Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O'Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood advances 6 (7) (2022)
Hamid Bolouri, Mary H Young, Joshua Beilke, Rebecca Johnson, Brian A Fox, Lu Huang, Cristina Costa Santini, Christopher Mark Hill, Anne-Renee van der Vuurst de Vries, Paul T Shannon, Andrew P Dervan, Pallavur Sivakumar, Matthew Trotter, Douglas Bassett, Alexander V Ratushny
Integrative network modeling reveals mechanisms underlying T cell exhaustion. Scientific reports 10 (1) (2020)

Brian A Fox.css-eqlu8i{font-size:small;padding-left:4px;} (Brian Fox)

Publication Activity (10 Years)

Top Topics

Top Venues

Brian A Fox (Brian Fox)